MX383833B - Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. - Google Patents
Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos.Info
- Publication number
- MX383833B MX383833B MX2018005242A MX2018005242A MX383833B MX 383833 B MX383833 B MX 383833B MX 2018005242 A MX2018005242 A MX 2018005242A MX 2018005242 A MX2018005242 A MX 2018005242A MX 383833 B MX383833 B MX 383833B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- compounds
- ion channel
- inhibitor compounds
- channel inhibitor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126181 ion channel inhibitor Drugs 0.000 title 1
- 108090000862 Ion Channels Proteins 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 abstract 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254564P | 2015-11-12 | 2015-11-12 | |
| PCT/US2016/061918 WO2017083867A1 (en) | 2015-11-12 | 2016-11-14 | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005242A MX2018005242A (es) | 2019-03-18 |
| MX383833B true MX383833B (es) | 2025-03-14 |
Family
ID=58696184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005242A MX383833B (es) | 2015-11-12 | 2016-11-14 | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10562857B2 (OSRAM) |
| EP (1) | EP3340988B1 (OSRAM) |
| JP (1) | JP6790094B2 (OSRAM) |
| KR (1) | KR102217524B1 (OSRAM) |
| CN (1) | CN108289886B (OSRAM) |
| AU (1) | AU2016353446B2 (OSRAM) |
| BR (1) | BR112018009439B1 (OSRAM) |
| CA (1) | CA3004448A1 (OSRAM) |
| IL (1) | IL259199B (OSRAM) |
| MX (1) | MX383833B (OSRAM) |
| NZ (1) | NZ742033A (OSRAM) |
| PH (1) | PH12018501000A1 (OSRAM) |
| RU (1) | RU2746188C2 (OSRAM) |
| SG (1) | SG11201803475YA (OSRAM) |
| WO (1) | WO2017083867A1 (OSRAM) |
| ZA (1) | ZA201803739B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220048913A1 (en) * | 2017-07-12 | 2022-02-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2018352828A1 (en) | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN110294717B (zh) * | 2018-03-21 | 2021-01-19 | 湖南加法检测有限公司 | 农药全组分中2,2-二取代环丁酮杂质及其衍生物、制备方法与应用 |
| CN108658933A (zh) * | 2018-07-13 | 2018-10-16 | 南京大学 | 一种二芳基并噻吩型或二芳基硫醚型氘代烷基的制备方法 |
| US11744825B2 (en) * | 2018-08-28 | 2023-09-05 | Afasci, Inc. | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
| WO2020223136A1 (en) | 2019-05-02 | 2020-11-05 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
| CN114340670A (zh) | 2019-07-11 | 2022-04-12 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| MX2022013595A (es) * | 2020-04-29 | 2023-01-24 | Praxis Prec Medicines Inc | Metodos de uso de moduladores del canal de calcio tipo t. |
| CN112574085A (zh) * | 2020-12-18 | 2021-03-30 | 南通药明康德医药科技有限公司 | 一种5-氨基-2-氮杂螺[3.4]辛烷-2-羧酸叔丁酯的制备方法 |
| JP2025505578A (ja) * | 2022-02-03 | 2025-02-28 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｔ型カルシウムチャネル調節因子を使用した治療方法 |
| KR20250165616A (ko) * | 2023-03-02 | 2025-11-26 | 프락시스 프리시젼 메디신즈, 인크. | 고함량 단일 투여 단위 제형 및 이의 사용 방법 |
| CN121013719A (zh) * | 2023-03-02 | 2025-11-25 | 普拉西斯精密医药公司 | 治疗特发性震颤的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126003A0 (en) | 1996-04-10 | 1999-04-11 | Hoechst Marion Roussel Inc | Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors |
| WO2007002361A2 (en) * | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine t-type calcium channel antagonists |
| CA2611639A1 (en) * | 2005-06-29 | 2007-01-04 | Merck & Co., Inc. | 4-fluoro-piperidine t-type calcium channel antagonists |
| DE102005030231B4 (de) | 2005-06-29 | 2007-05-31 | Forschungszentrum Karlsruhe Gmbh | Verfahren zum Aufbringen einer hochtemperaturgeeigneten FeCrAl-Schutzschicht, Hüllrohr mit einer derartig aufgebrachten Schutzschicht und Verwendung eines solchen Hüllrohrs |
| WO2008151702A1 (en) * | 2007-06-15 | 2008-12-18 | Newron Pharmaceuticals S.P.A. | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
| US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| WO2012125662A1 (en) * | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Indole derivatives useful as ccr2 antagonists |
| AU2012311698B2 (en) * | 2011-09-22 | 2017-06-22 | Merck Sharp & Dohme B.V. | N-piperidin-4-yl derivatives |
| ES2620668T3 (es) | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
| KR101556318B1 (ko) * | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
| CN110698481B (zh) * | 2013-07-03 | 2023-02-28 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
| JP2017001954A (ja) * | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
-
2016
- 2016-11-14 AU AU2016353446A patent/AU2016353446B2/en active Active
- 2016-11-14 US US15/772,365 patent/US10562857B2/en active Active
- 2016-11-14 CA CA3004448A patent/CA3004448A1/en active Pending
- 2016-11-14 BR BR112018009439-0A patent/BR112018009439B1/pt active IP Right Grant
- 2016-11-14 KR KR1020187013376A patent/KR102217524B1/ko active Active
- 2016-11-14 RU RU2018121288A patent/RU2746188C2/ru active
- 2016-11-14 EP EP16865245.1A patent/EP3340988B1/en active Active
- 2016-11-14 WO PCT/US2016/061918 patent/WO2017083867A1/en not_active Ceased
- 2016-11-14 CN CN201680066520.XA patent/CN108289886B/zh active Active
- 2016-11-14 NZ NZ742033A patent/NZ742033A/en unknown
- 2016-11-14 JP JP2018523749A patent/JP6790094B2/ja active Active
- 2016-11-14 MX MX2018005242A patent/MX383833B/es unknown
- 2016-11-14 SG SG11201803475YA patent/SG11201803475YA/en unknown
-
2018
- 2018-05-08 PH PH12018501000A patent/PH12018501000A1/en unknown
- 2018-05-08 IL IL259199A patent/IL259199B/en unknown
- 2018-06-06 ZA ZA2018/03739A patent/ZA201803739B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3004448A1 (en) | 2017-05-18 |
| EP3340988A4 (en) | 2019-05-15 |
| ZA201803739B (en) | 2019-04-24 |
| RU2018121288A3 (OSRAM) | 2020-03-27 |
| AU2016353446B2 (en) | 2022-05-19 |
| CN108289886A (zh) | 2018-07-17 |
| NZ742033A (en) | 2022-11-25 |
| JP2018533593A (ja) | 2018-11-15 |
| EP3340988A1 (en) | 2018-07-04 |
| EP3340988B1 (en) | 2025-04-09 |
| BR112018009439B1 (pt) | 2023-12-12 |
| PH12018501000A1 (en) | 2019-01-28 |
| KR20180074705A (ko) | 2018-07-03 |
| CN108289886B (zh) | 2022-01-28 |
| JP6790094B2 (ja) | 2020-11-25 |
| KR102217524B1 (ko) | 2021-02-19 |
| US20180312471A1 (en) | 2018-11-01 |
| WO2017083867A1 (en) | 2017-05-18 |
| RU2746188C2 (ru) | 2021-04-08 |
| BR112018009439A2 (pt) | 2018-12-04 |
| IL259199A (en) | 2018-07-31 |
| US10562857B2 (en) | 2020-02-18 |
| AU2016353446A1 (en) | 2018-05-24 |
| HK1254407A1 (zh) | 2019-07-19 |
| RU2018121288A (ru) | 2019-12-16 |
| MX2018005242A (es) | 2019-03-18 |
| IL259199B (en) | 2022-03-01 |
| EP3340988C0 (en) | 2025-04-09 |
| SG11201803475YA (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383833B (es) | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. | |
| ZA202004100B (en) | Diaryl macrocycles as modulators of protein kinases | |
| MX2017003624A (es) | Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas. | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| EA201991553A1 (ru) | (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды | |
| EA202090019A1 (ru) | Спироциклические индолины в качестве модуляторов il-17 | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| MX2014012266A (es) | Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos. | |
| MX383930B (es) | Compuestos de pirazol sustituidos como inhibidores de serina proteasa. | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EP3712264A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
| EA201991898A1 (ru) | Двойные ингибиторы magl и faah | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2018004220A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2020005545A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
| WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| WO2021257697A8 (en) | Compounds and methods for blocking apoptosis and inducing autophagy | |
| MX2021015898A (es) | Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d. | |
| MX2018004217A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
| CA3085227C (en) | Phenoxiacetic acids for the treatment of neuromuscular disorders |